| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | type I interferon receptor binding | 6.82e-17 | 17 | 27 | 7 | GO:0005132 | |
| GeneOntologyMolecularFunction | disaccharide binding | 9.25e-11 | 7 | 27 | 4 | GO:0048030 | |
| GeneOntologyMolecularFunction | oligosaccharide binding | 1.27e-08 | 20 | 27 | 4 | GO:0070492 | |
| GeneOntologyMolecularFunction | cytokine activity | 3.18e-08 | 250 | 27 | 7 | GO:0005125 | |
| GeneOntologyMolecularFunction | galactoside binding | 1.84e-07 | 9 | 27 | 3 | GO:0016936 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 1.87e-07 | 324 | 27 | 7 | GO:0005126 | |
| GeneOntologyMolecularFunction | molecular function activator activity | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.48e-07 | 1233 | 27 | 11 | GO:0140677 |
| GeneOntologyMolecularFunction | receptor ligand activity | 4.23e-07 | 547 | 27 | 8 | GO:0048018 | |
| GeneOntologyMolecularFunction | signaling receptor activator activity | 4.65e-07 | 554 | 27 | 8 | GO:0030546 | |
| GeneOntologyMolecularFunction | signaling receptor regulator activity | 1.04e-06 | 616 | 27 | 8 | GO:0030545 | |
| GeneOntologyMolecularFunction | carbohydrate binding | 5.32e-05 | 310 | 27 | 5 | GO:0030246 | |
| GeneOntologyMolecularFunction | protein serine/threonine kinase activator activity | 1.57e-04 | 78 | 27 | 3 | GO:0043539 | |
| GeneOntologyMolecularFunction | protein kinase activator activity | 1.04e-03 | 149 | 27 | 3 | GO:0030295 | |
| GeneOntologyMolecularFunction | kinase activator activity | 1.26e-03 | 159 | 27 | 3 | GO:0019209 | |
| GeneOntologyMolecularFunction | protein kinase regulator activity | 5.01e-03 | 259 | 27 | 3 | GO:0019887 | |
| GeneOntologyMolecularFunction | monosaccharide binding | 7.28e-03 | 95 | 27 | 2 | GO:0048029 | |
| GeneOntologyMolecularFunction | kinase regulator activity | 7.87e-03 | 305 | 27 | 3 | GO:0019207 | |
| GeneOntologyBiologicalProcess | natural killer cell activation involved in immune response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 4.91e-21 | 42 | 28 | 10 | GO:0002323 |
| GeneOntologyBiologicalProcess | cellular response to virus | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 1.84e-17 | 90 | 28 | 10 | GO:0098586 |
| GeneOntologyBiologicalProcess | positive regulation of peptidyl-serine phosphorylation of STAT protein | 4.32e-16 | 21 | 28 | 7 | GO:0033141 | |
| GeneOntologyBiologicalProcess | natural killer cell activation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 5.10e-16 | 124 | 28 | 10 | GO:0030101 |
| GeneOntologyBiologicalProcess | regulation of peptidyl-serine phosphorylation of STAT protein | 1.28e-15 | 24 | 28 | 7 | GO:0033139 | |
| GeneOntologyBiologicalProcess | serine phosphorylation of STAT protein | 4.37e-15 | 28 | 28 | 7 | GO:0042501 | |
| GeneOntologyBiologicalProcess | lymphocyte activation involved in immune response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 1.25e-14 | 251 | 28 | 11 | GO:0002285 |
| GeneOntologyBiologicalProcess | T cell activation involved in immune response | 2.43e-13 | 148 | 28 | 9 | GO:0002286 | |
| GeneOntologyBiologicalProcess | leukocyte activation involved in immune response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 6.68e-13 | 361 | 28 | 11 | GO:0002366 |
| GeneOntologyBiologicalProcess | response to exogenous dsRNA | 7.31e-13 | 55 | 28 | 7 | GO:0043330 | |
| GeneOntologyBiologicalProcess | cell activation involved in immune response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 7.53e-13 | 365 | 28 | 11 | GO:0002263 |
| GeneOntologyBiologicalProcess | lymphocyte proliferation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 1.93e-12 | 398 | 28 | 11 | GO:0046651 |
| GeneOntologyBiologicalProcess | response to dsRNA | 1.98e-12 | 63 | 28 | 7 | GO:0043331 | |
| GeneOntologyBiologicalProcess | mononuclear cell proliferation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.39e-12 | 406 | 28 | 11 | GO:0032943 |
| GeneOntologyBiologicalProcess | leukocyte proliferation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 6.44e-12 | 445 | 28 | 11 | GO:0070661 |
| GeneOntologyBiologicalProcess | type I interferon-mediated signaling pathway | 1.73e-11 | 85 | 28 | 7 | GO:0060337 | |
| GeneOntologyBiologicalProcess | cellular response to type I interferon | 1.88e-11 | 86 | 28 | 7 | GO:0071357 | |
| GeneOntologyBiologicalProcess | response to type I interferon | 3.05e-11 | 92 | 28 | 7 | GO:0034340 | |
| GeneOntologyBiologicalProcess | positive regulation of peptidyl-serine phosphorylation | 5.95e-11 | 101 | 28 | 7 | GO:0033138 | |
| GeneOntologyBiologicalProcess | response to virus | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 1.17e-10 | 425 | 28 | 10 | GO:0009615 |
| GeneOntologyBiologicalProcess | interferon-mediated signaling pathway | 1.24e-10 | 112 | 28 | 7 | GO:0140888 | |
| GeneOntologyBiologicalProcess | regulation of defense response to virus by host | 2.27e-10 | 63 | 28 | 6 | GO:0050691 | |
| GeneOntologyBiologicalProcess | B cell proliferation | 2.55e-10 | 124 | 28 | 7 | GO:0042100 | |
| GeneOntologyBiologicalProcess | regulation of receptor signaling pathway via JAK-STAT | 2.70e-10 | 125 | 28 | 7 | GO:0046425 | |
| GeneOntologyBiologicalProcess | adaptive immune response | LGALS9C TRBV5-3 GFUS LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 3.12e-10 | 838 | 28 | 12 | GO:0002250 |
| GeneOntologyBiologicalProcess | mononuclear cell differentiation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 3.13e-10 | 640 | 28 | 11 | GO:1903131 |
| GeneOntologyBiologicalProcess | immune effector process | LGALS9C GFUS LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 4.15e-10 | 859 | 28 | 12 | GO:0002252 |
| GeneOntologyBiologicalProcess | regulation of peptidyl-serine phosphorylation | 5.15e-10 | 137 | 28 | 7 | GO:0033135 | |
| GeneOntologyBiologicalProcess | regulation of receptor signaling pathway via STAT | 6.96e-10 | 143 | 28 | 7 | GO:1904892 | |
| GeneOntologyBiologicalProcess | T cell activation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 8.19e-10 | 701 | 28 | 11 | GO:0042110 |
| GeneOntologyBiologicalProcess | lymphocyte differentiation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 1.13e-09 | 537 | 28 | 10 | GO:0030098 |
| GeneOntologyBiologicalProcess | defense response to bacterium | LGALS9C LGALS9B IFNA2 IFNA4 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 1.97e-09 | 405 | 28 | 9 | GO:0042742 |
| GeneOntologyBiologicalProcess | regulation of defense response to virus | 2.03e-09 | 90 | 28 | 6 | GO:0050688 | |
| GeneOntologyBiologicalProcess | leukocyte differentiation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.83e-09 | 789 | 28 | 11 | GO:0002521 |
| GeneOntologyBiologicalProcess | innate immune response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 MPTX1 IFNA17 IFNA21 LGALS9 | 6.31e-09 | 1092 | 28 | 12 | GO:0045087 |
| GeneOntologyBiologicalProcess | cell surface receptor signaling pathway via JAK-STAT | 6.74e-09 | 198 | 28 | 7 | GO:0007259 | |
| GeneOntologyBiologicalProcess | humoral immune response | 7.48e-09 | 321 | 28 | 8 | GO:0006959 | |
| GeneOntologyBiologicalProcess | B cell differentiation | 7.48e-09 | 201 | 28 | 7 | GO:0030183 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell degranulation | 8.95e-09 | 4 | 28 | 3 | GO:0043322 | |
| GeneOntologyBiologicalProcess | cell surface receptor signaling pathway via STAT | 1.23e-08 | 216 | 28 | 7 | GO:0097696 | |
| GeneOntologyBiologicalProcess | negative regulation of cell population proliferation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.20e-08 | 961 | 28 | 11 | GO:0008285 |
| GeneOntologyBiologicalProcess | lymphocyte activation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.58e-08 | 976 | 28 | 11 | GO:0046649 |
| GeneOntologyBiologicalProcess | defense response to symbiont | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 MPTX1 IFNA17 IFNA21 LGALS9 | 3.92e-08 | 1286 | 28 | 12 | GO:0140546 |
| GeneOntologyBiologicalProcess | defense response to other organism | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 MPTX1 IFNA17 IFNA21 LGALS9 | 1.06e-07 | 1407 | 28 | 12 | GO:0098542 |
| GeneOntologyBiologicalProcess | regulation of response to biotic stimulus | LGALS9C LGALS9B IFNA2 IFNA4 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 1.07e-07 | 643 | 28 | 9 | GO:0002831 |
| GeneOntologyBiologicalProcess | regulation of natural killer cell degranulation | 1.25e-07 | 8 | 28 | 3 | GO:0043321 | |
| GeneOntologyBiologicalProcess | peptidyl-serine phosphorylation | 1.37e-07 | 307 | 28 | 7 | GO:0018105 | |
| GeneOntologyBiologicalProcess | peptidyl-serine modification | 1.78e-07 | 319 | 28 | 7 | GO:0018209 | |
| GeneOntologyBiologicalProcess | leukocyte activation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 1.88e-07 | 1186 | 28 | 11 | GO:0045321 |
| GeneOntologyBiologicalProcess | hemopoiesis | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 2.56e-07 | 1223 | 28 | 11 | GO:0030097 |
| GeneOntologyBiologicalProcess | positive regulation of mononuclear cell migration | 2.65e-07 | 104 | 28 | 5 | GO:0071677 | |
| GeneOntologyBiologicalProcess | B cell activation | 2.79e-07 | 341 | 28 | 7 | GO:0042113 | |
| GeneOntologyBiologicalProcess | defense response to virus | 2.84e-07 | 342 | 28 | 7 | GO:0051607 | |
| GeneOntologyBiologicalProcess | cell activation | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 7.21e-07 | 1356 | 28 | 11 | GO:0001775 |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell activation | 1.01e-06 | 15 | 28 | 3 | GO:0032815 | |
| GeneOntologyBiologicalProcess | negative regulation of CD4-positive, alpha-beta T cell proliferation | 1.01e-06 | 15 | 28 | 3 | GO:2000562 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte degranulation | 1.50e-06 | 17 | 28 | 3 | GO:0043301 | |
| GeneOntologyBiologicalProcess | natural killer cell degranulation | 1.80e-06 | 18 | 28 | 3 | GO:0043320 | |
| GeneOntologyBiologicalProcess | response to bacterium | LGALS9C LGALS9B IFNA2 IFNA4 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 2.08e-06 | 916 | 28 | 9 | GO:0009617 |
| GeneOntologyBiologicalProcess | negative regulation of alpha-beta T cell proliferation | 2.14e-06 | 19 | 28 | 3 | GO:0046642 | |
| GeneOntologyBiologicalProcess | positive regulation of defense response to bacterium | 2.14e-06 | 19 | 28 | 3 | GO:1900426 | |
| GeneOntologyBiologicalProcess | regulation of mononuclear cell migration | 2.24e-06 | 160 | 28 | 5 | GO:0071675 | |
| GeneOntologyBiologicalProcess | regulation of T cell chemotaxis | 2.51e-06 | 20 | 28 | 3 | GO:0010819 | |
| GeneOntologyBiologicalProcess | negative regulation of immune effector process | 2.69e-06 | 166 | 28 | 5 | GO:0002698 | |
| GeneOntologyBiologicalProcess | regulation of natural killer cell differentiation | 2.93e-06 | 21 | 28 | 3 | GO:0032823 | |
| GeneOntologyBiologicalProcess | negative regulation of T cell activation | 3.11e-06 | 171 | 28 | 5 | GO:0050868 | |
| GeneOntologyBiologicalProcess | positive regulation of leukocyte migration | 3.89e-06 | 179 | 28 | 5 | GO:0002687 | |
| GeneOntologyBiologicalProcess | regulation of defense response | LGALS9C LGALS9B IFNA2 IFNA4 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 4.49e-06 | 1006 | 28 | 9 | GO:0031347 |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte mediated immunity | 4.64e-06 | 83 | 28 | 4 | GO:0002707 | |
| GeneOntologyBiologicalProcess | regulation of response to external stimulus | LGALS9C LGALS9B ANO6 IFNA2 IFNA4 IFNA6 IFNA14 IFNA17 IFNA21 LGALS9 | 4.91e-06 | 1316 | 28 | 10 | GO:0032101 |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte cell-cell adhesion | 5.48e-06 | 192 | 28 | 5 | GO:1903038 | |
| GeneOntologyBiologicalProcess | regulation of defense response to bacterium | 5.70e-06 | 26 | 28 | 3 | GO:1900424 | |
| GeneOntologyBiologicalProcess | regulation of CD4-positive, alpha-beta T cell proliferation | 7.17e-06 | 28 | 28 | 3 | GO:2000561 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte mediated immunity | 8.28e-06 | 96 | 28 | 4 | GO:0002704 | |
| GeneOntologyBiologicalProcess | negative regulation of lymphocyte activation | 8.67e-06 | 211 | 28 | 5 | GO:0051250 | |
| GeneOntologyBiologicalProcess | CD4-positive, alpha-beta T cell proliferation | 8.88e-06 | 30 | 28 | 3 | GO:0035739 | |
| GeneOntologyBiologicalProcess | cytokine-mediated signaling pathway | 9.18e-06 | 577 | 28 | 7 | GO:0019221 | |
| GeneOntologyBiologicalProcess | regulation of lymphocyte chemotaxis | 9.82e-06 | 31 | 28 | 3 | GO:1901623 | |
| GeneOntologyBiologicalProcess | positive regulation of regulatory T cell differentiation | 9.82e-06 | 31 | 28 | 3 | GO:0045591 | |
| GeneOntologyBiologicalProcess | negative regulation of regulated secretory pathway | 1.08e-05 | 32 | 28 | 3 | GO:1903306 | |
| GeneOntologyBiologicalProcess | T cell chemotaxis | 1.19e-05 | 33 | 28 | 3 | GO:0010818 | |
| GeneOntologyBiologicalProcess | maintenance of protein location | 1.53e-05 | 112 | 28 | 4 | GO:0045185 | |
| GeneOntologyBiologicalProcess | negative regulation of immune response | 1.58e-05 | 239 | 28 | 5 | GO:0050777 | |
| GeneOntologyBiologicalProcess | negative regulation of leukocyte activation | 1.62e-05 | 240 | 28 | 5 | GO:0002695 | |
| GeneOntologyBiologicalProcess | regulation of T cell differentiation in thymus | 1.69e-05 | 37 | 28 | 3 | GO:0033081 | |
| GeneOntologyBiologicalProcess | natural killer cell differentiation | 1.83e-05 | 38 | 28 | 3 | GO:0001779 | |
| GeneOntologyBiologicalProcess | negative regulation of cell-cell adhesion | 2.04e-05 | 252 | 28 | 5 | GO:0022408 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated cytotoxicity | 2.14e-05 | 40 | 28 | 3 | GO:0045953 | |
| GeneOntologyBiologicalProcess | negative regulation of CD4-positive, alpha-beta T cell activation | 2.14e-05 | 40 | 28 | 3 | GO:2000515 | |
| GeneOntologyBiologicalProcess | mononuclear cell migration | 2.29e-05 | 258 | 28 | 5 | GO:0071674 | |
| GeneOntologyBiologicalProcess | positive regulation of T cell migration | 2.31e-05 | 41 | 28 | 3 | GO:2000406 | |
| GeneOntologyBiologicalProcess | negative regulation of natural killer cell mediated immunity | 2.31e-05 | 41 | 28 | 3 | GO:0002716 | |
| GeneOntologyBiologicalProcess | positive regulation of macrophage activation | 2.48e-05 | 42 | 28 | 3 | GO:0043032 | |
| GeneOntologyBiologicalProcess | negative regulation of cell activation | 2.55e-05 | 264 | 28 | 5 | GO:0050866 | |
| GeneOntologyBiologicalProcess | regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell | 2.66e-05 | 6 | 28 | 2 | GO:2001188 | |
| GeneOntologyBiologicalProcess | positive regulation of SMAD protein signal transduction | 2.67e-05 | 43 | 28 | 3 | GO:0060391 | |
| GeneOntologyBiologicalProcess | regulation of leukocyte migration | 2.70e-05 | 267 | 28 | 5 | GO:0002685 | |
| GeneOntologyBiologicalProcess | leukocyte chemotaxis | 2.70e-05 | 267 | 28 | 5 | GO:0030595 | |
| GeneOntologyBiologicalProcess | cellular response to cytokine stimulus | 3.05e-05 | 967 | 28 | 8 | GO:0071345 | |
| GeneOntologyBiologicalProcess | negative regulation of exocytosis | 3.06e-05 | 45 | 28 | 3 | GO:0045920 | |
| GeneOntologyCellularComponent | collagen-containing extracellular matrix | 6.05e-05 | 530 | 28 | 6 | GO:0062023 | |
| GeneOntologyCellularComponent | extracellular matrix | 1.95e-04 | 656 | 28 | 6 | GO:0031012 | |
| GeneOntologyCellularComponent | external encapsulating structure | 1.98e-04 | 658 | 28 | 6 | GO:0030312 | |
| MousePheno | enhanced humoral immune response | 1.43e-06 | 17 | 19 | 3 | MP:0020155 | |
| MousePheno | increased T-helper 1 cell number | 2.03e-06 | 19 | 19 | 3 | MP:0008086 | |
| MousePheno | abnormal lymph node germinal center morphology | 3.71e-06 | 23 | 19 | 3 | MP:0008522 | |
| MousePheno | increased spleen germinal center size | 3.71e-06 | 23 | 19 | 3 | MP:0008483 | |
| MousePheno | abnormal T-helper 1 cell number | 4.23e-06 | 24 | 19 | 3 | MP:0008085 | |
| MousePheno | abnormal lymph node secondary follicle morphology | 4.80e-06 | 25 | 19 | 3 | MP:0002346 | |
| MousePheno | lymph node hyperplasia | 1.13e-05 | 33 | 19 | 3 | MP:0008102 | |
| MousePheno | thymus hyperplasia | 1.24e-05 | 34 | 19 | 3 | MP:0000708 | |
| MousePheno | increased susceptibility to induced arthritis | 1.48e-05 | 36 | 19 | 3 | MP:0003724 | |
| MousePheno | abnormal lymph node B cell domain morphology | 2.72e-05 | 44 | 19 | 3 | MP:0002344 | |
| MousePheno | abnormal T-helper 1 cell morphology | 3.54e-05 | 48 | 19 | 3 | MP:0002433 | |
| MousePheno | abnormal lymph node cortex morphology | 4.01e-05 | 50 | 19 | 3 | MP:0002343 | |
| MousePheno | increased T-helper cell number | 5.64e-05 | 56 | 19 | 3 | MP:0013763 | |
| MousePheno | decreased regulatory T cell number | 8.42e-05 | 64 | 19 | 3 | MP:0004974 | |
| MousePheno | increased B cell proliferation | 1.35e-04 | 75 | 19 | 3 | MP:0005154 | |
| MousePheno | abnormal Peyer's patch morphology | 1.83e-04 | 83 | 19 | 3 | MP:0000696 | |
| MousePheno | abnormal gut-associated lymphoid tissue morphology | 1.96e-04 | 85 | 19 | 3 | MP:0002378 | |
| MousePheno | spleen hyperplasia | 1.96e-04 | 85 | 19 | 3 | MP:0000693 | |
| MousePheno | abnormal CD4-positive helper T cell morphology | 3.17e-04 | 100 | 19 | 3 | MP:0010183 | |
| MousePheno | abnormal spleen germinal center morphology | 3.86e-04 | 107 | 19 | 3 | MP:0002359 | |
| MousePheno | autoimmune arthritis | 3.97e-04 | 108 | 19 | 3 | MP:0002993 | |
| MousePheno | abnormal spleen secondary B follicle morphology | 4.08e-04 | 109 | 19 | 3 | MP:0008472 | |
| MousePheno | abnormal T-helper cell number | 4.65e-04 | 114 | 19 | 3 | MP:0013761 | |
| MousePheno | abnormal regulatory T cell number | 4.77e-04 | 115 | 19 | 3 | MP:0004972 | |
| MousePheno | abnormal regulatory T cell morphology | 5.02e-04 | 117 | 19 | 3 | MP:0004941 | |
| MousePheno | joint inflammation | 6.98e-04 | 131 | 19 | 3 | MP:0002933 | |
| MousePheno | abnormal spleen B cell follicle morphology | 9.19e-04 | 144 | 19 | 3 | MP:0008470 | |
| MousePheno | abnormal joint physiology | 9.38e-04 | 145 | 19 | 3 | MP:0031169 | |
| MousePheno | increased granulocyte number | 9.86e-04 | 597 | 19 | 5 | MP:0000322 | |
| MousePheno | abnormal T-helper cell morphology | 1.01e-03 | 149 | 19 | 3 | MP:0013760 | |
| MousePheno | abnormal B cell proliferation | 1.07e-03 | 152 | 19 | 3 | MP:0005153 | |
| MousePheno | increased susceptibility to autoimmune disorder | 1.14e-03 | 155 | 19 | 3 | MP:0005350 | |
| MousePheno | abnormal skeleton physiology | 1.27e-03 | 632 | 19 | 5 | MP:0001533 | |
| MousePheno | increased neutrophil cell number | 1.34e-03 | 368 | 19 | 4 | MP:0000219 | |
| MousePheno | abnormal B cell activation | 1.39e-03 | 166 | 19 | 3 | MP:0008217 | |
| MousePheno | abnormal effector T cell number | 2.46e-03 | 203 | 19 | 3 | MP:0013762 | |
| MousePheno | increased circulating creatinine level | 3.46e-03 | 229 | 19 | 3 | MP:0005553 | |
| MousePheno | abnormal granulocyte number | 3.70e-03 | 805 | 19 | 5 | MP:0020201 | |
| MousePheno | increased CD4-positive, alpha-beta T cell number | 4.00e-03 | 241 | 19 | 3 | MP:0008074 | |
| MousePheno | abnormal neutrophil cell number | 4.06e-03 | 499 | 19 | 4 | MP:0012440 | |
| MousePheno | enlarged lymph nodes | 4.29e-03 | 507 | 19 | 4 | MP:0000702 | |
| MousePheno | abnormal granulocyte morphology | 4.33e-03 | 835 | 19 | 5 | MP:0002441 | |
| MousePheno | abnormal neutrophil morphology | 4.42e-03 | 511 | 19 | 4 | MP:0005065 | |
| Domain | IFabd | 5.90e-17 | 17 | 25 | 7 | SM00076 | |
| Domain | Interferon_alpha/beta/delta | 5.90e-17 | 17 | 25 | 7 | IPR000471 | |
| Domain | INTERFERON_A_B_D | 5.90e-17 | 17 | 25 | 7 | PS00252 | |
| Domain | Interferon | 5.90e-17 | 17 | 25 | 7 | PF00143 | |
| Domain | - | 2.95e-13 | 50 | 25 | 7 | 1.20.1250.10 | |
| Domain | 4_helix_cytokine_core | 3.41e-13 | 51 | 25 | 7 | IPR012351 | |
| Domain | 4_helix_cytokine-like_core | 5.20e-12 | 74 | 25 | 7 | IPR009079 | |
| Domain | Gal-bind_lectin | 3.37e-09 | 15 | 25 | 4 | SM00908 | |
| Domain | Gal-bind_lectin | 3.37e-09 | 15 | 25 | 4 | PF00337 | |
| Domain | GALECTIN | 3.37e-09 | 15 | 25 | 4 | PS51304 | |
| Domain | GLECT | 3.37e-09 | 15 | 25 | 4 | SM00276 | |
| Domain | Galectin_CRD | 3.37e-09 | 15 | 25 | 4 | IPR001079 | |
| Domain | - | 7.32e-06 | 95 | 25 | 4 | 2.60.120.200 | |
| Domain | ConA-like_dom | 9.29e-06 | 219 | 25 | 5 | IPR013320 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HIV_TAT_TO_TLR2_4_NFKB_SIGNALING_PATHWAY | 4.44e-17 | 17 | 19 | 7 | M47564 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CGAS_STING_SIGNALING_PATHWAY | 7.26e-17 | 18 | 19 | 7 | M47539 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR3_IRF7_SIGNALING_PATHWAY | 1.15e-16 | 19 | 19 | 7 | M47450 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR7_9_IRF7_SIGNALING_PATHWAY | 1.76e-16 | 20 | 19 | 7 | M47617 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_II_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY | 2.65e-16 | 21 | 19 | 7 | M47909 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR7_8_9_IRF5_SIGNALING_PATHWAY | 3.88e-16 | 22 | 19 | 7 | M47897 | |
| Pathway | KEGG_MEDICUS_REFERENCE_RIG_I_NFKB_SIGNALING_PATHWAY | 3.88e-16 | 22 | 19 | 7 | M47616 | |
| Pathway | REACTOME_REGULATION_OF_IFNA_IFNB_SIGNALING | 5.57e-16 | 23 | 19 | 7 | MM15634 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_I_IFN_SIGNALING_PATHWAY | 5.57e-16 | 23 | 19 | 7 | M47452 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MDA5_IRF7_3_SIGNALING_PATHWAY | 7.86e-16 | 24 | 19 | 7 | M47782 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_I_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY | 7.86e-16 | 24 | 19 | 7 | M47908 | |
| Pathway | KEGG_MEDICUS_REFERENCE_RIG_I_IRF7_3_SIGNALING_PATHWAY | 7.86e-16 | 24 | 19 | 7 | M47576 | |
| Pathway | REACTOME_REGULATION_OF_IFNA_IFNB_SIGNALING | 1.49e-15 | 26 | 19 | 7 | M982 | |
| Pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 4.60e-15 | 30 | 19 | 7 | M936 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IFN_RIPK1_3_SIGNALING_PATHWAY | 5.94e-15 | 31 | 19 | 7 | M47964 | |
| Pathway | WP_SARS_CORONAVIRUS_AND_INNATE_IMMUNITY | 5.94e-15 | 31 | 19 | 7 | M39897 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 1.21e-14 | 34 | 19 | 7 | MM15631 | |
| Pathway | KEGG_REGULATION_OF_AUTOPHAGY | 1.51e-14 | 35 | 19 | 7 | M6382 | |
| Pathway | REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES | 1.51e-14 | 35 | 19 | 7 | M48246 | |
| Pathway | WP_INTERFERONMEDIATED_SIGNALING | 2.31e-14 | 37 | 19 | 7 | M39785 | |
| Pathway | BIOCARTA_IFNA_PATHWAY | 6.69e-14 | 19 | 19 | 6 | MM1571 | |
| Pathway | KEGG_AUTOIMMUNE_THYROID_DISEASE | 2.97e-13 | 52 | 19 | 7 | M13103 | |
| Pathway | KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY | 4.50e-13 | 55 | 19 | 7 | M11844 | |
| Pathway | BIOCARTA_CYTOKINE_PATHWAY | 9.23e-13 | 28 | 19 | 6 | MM1378 | |
| Pathway | PID_CD8_TCR_DOWNSTREAM_PATHWAY | 1.53e-12 | 65 | 19 | 7 | M272 | |
| Pathway | BIOCARTA_INFLAM_PATHWAY | 2.70e-12 | 33 | 19 | 6 | MM1379 | |
| Pathway | KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY | 2.91e-12 | 71 | 19 | 7 | M15913 | |
| Pathway | WP_CYTOSOLIC_DNASENSING_PATHWAY | 3.57e-12 | 73 | 19 | 7 | M39837 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 5.76e-12 | 78 | 19 | 7 | M973 | |
| Pathway | WP_CYTOKINES_AND_INFLAMMATORY_RESPONSE | 7.92e-12 | 39 | 19 | 6 | MM15914 | |
| Pathway | REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA | 8.26e-12 | 82 | 19 | 7 | M1002 | |
| Pathway | BIOCARTA_IL1R_PATHWAY | 1.09e-11 | 41 | 19 | 6 | MM1493 | |
| Pathway | KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 1.37e-11 | 88 | 19 | 7 | M16004 | |
| Pathway | REACTOME_RSV_HOST_INTERACTIONS | 2.97e-11 | 98 | 19 | 7 | M48247 | |
| Pathway | KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | 3.95e-11 | 102 | 19 | 7 | M3261 | |
| Pathway | WP_TOLLLIKE_RECEPTOR_SIGNALING | 4.24e-11 | 103 | 19 | 7 | M39434 | |
| Pathway | REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY | 1.26e-10 | 120 | 19 | 7 | M48233 | |
| Pathway | REACTOME_SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES | 1.78e-10 | 126 | 19 | 7 | M45009 | |
| Pathway | WP_OVERVIEW_OF_PROINFLAMMATORY_AND_PROFIBROTIC_MEDIATORS | 1.88e-10 | 127 | 19 | 7 | M42533 | |
| Pathway | WP_MEASLES_VIRUS_INFECTION | 3.05e-10 | 136 | 19 | 7 | M42547 | |
| Pathway | KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 3.21e-10 | 137 | 19 | 7 | M5669 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 3.38e-10 | 138 | 19 | 7 | MM15635 | |
| Pathway | WP_HEPATITIS_B_INFECTION | 6.37e-10 | 151 | 19 | 7 | M39801 | |
| Pathway | KEGG_JAK_STAT_SIGNALING_PATHWAY | 7.65e-10 | 155 | 19 | 7 | M17411 | |
| Pathway | WP_IL2_SIGNALING_PATHWAY | 1.18e-09 | 87 | 19 | 6 | MM15915 | |
| Pathway | REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION | 1.46e-09 | 170 | 19 | 7 | M941 | |
| Pathway | REACTOME_SARS_COV_2_INFECTION | 2.30e-09 | 299 | 19 | 8 | M41727 | |
| Pathway | REACTOME_SARS_COV_2_HOST_INTERACTIONS | 5.21e-09 | 204 | 19 | 7 | M45011 | |
| Pathway | KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 3.10e-08 | 264 | 19 | 7 | M9809 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 3.91e-08 | 273 | 19 | 7 | M983 | |
| Pathway | REACTOME_SARS_COV_INFECTIONS | 8.00e-08 | 471 | 19 | 8 | M39009 | |
| Pathway | WP_FOCAL_ADHESION_PI3KAKTMTOR_SIGNALING_PATHWAY | 1.32e-07 | 326 | 19 | 7 | MM15917 | |
| Pathway | WP_PI3KAKT_SIGNALING | 1.72e-07 | 339 | 19 | 7 | M39736 | |
| Pathway | REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | 1.60e-06 | 472 | 19 | 7 | MM14539 | |
| Pathway | WP_CANCER_PATHWAYS | 2.58e-06 | 507 | 19 | 7 | M48302 | |
| Pathway | REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | 4.04e-06 | 789 | 19 | 8 | M1060 | |
| Pathway | REACTOME_INNATE_IMMUNE_SYSTEM | 5.76e-06 | 1128 | 19 | 9 | M1036 | |
| Pathway | REACTOME_VIRAL_INFECTION_PATHWAYS | 9.73e-06 | 888 | 19 | 8 | M48034 | |
| Pathway | REACTOME_HEMOSTASIS | 1.77e-05 | 679 | 19 | 7 | M8395 | |
| Pathway | REACTOME_INFECTIOUS_DISEASE | 4.09e-05 | 1081 | 19 | 8 | M27548 | |
| Pathway | WP_IMMUNE_INFILTRATION_IN_PANCREATIC_CANCER | 1.24e-03 | 39 | 19 | 2 | M46456 | |
| Pathway | WP_T_CELL_MODULATION_IN_PANCREATIC_CANCER | 1.72e-03 | 46 | 19 | 2 | M46466 | |
| Pathway | WP_SPINAL_CORD_INJURY | 1.07e-02 | 117 | 19 | 2 | M39341 | |
| Pathway | REACTOME_L1CAM_INTERACTIONS | 1.14e-02 | 121 | 19 | 2 | M872 | |
| Pubmed | 7.66e-20 | 12 | 28 | 7 | 16565497 | ||
| Pubmed | Identification of distal silencing elements in the murine interferon-A11 gene promoter. | 7.66e-20 | 12 | 28 | 7 | 8760352 | |
| Pubmed | Evolution of the interferon alpha gene family in eutherian mammals. | 7.66e-20 | 12 | 28 | 7 | 17512142 | |
| Pubmed | Repression of the murine interferon alpha 11 gene: identification of negatively acting sequences. | 7.66e-20 | 12 | 28 | 7 | 1886773 | |
| Pubmed | Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. | 7.66e-20 | 12 | 28 | 7 | 22912583 | |
| Pubmed | 7.66e-20 | 12 | 28 | 7 | 17451966 | ||
| Pubmed | Structure and expression of a new murine interferon-alpha gene: MuIFN-alpha I9. | 7.66e-20 | 12 | 28 | 7 | 3758677 | |
| Pubmed | 7.66e-20 | 12 | 28 | 7 | 11846978 | ||
| Pubmed | Role of interferons in the regulation of cell proliferation, differentiation, and development. | 7.66e-20 | 12 | 28 | 7 | 7530016 | |
| Pubmed | 7.66e-20 | 12 | 28 | 7 | 9794206 | ||
| Pubmed | Multiple pathways of interferon-induced gene expression in murine macrophages. | 7.66e-20 | 12 | 28 | 7 | 7684767 | |
| Pubmed | Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. | 7.66e-20 | 12 | 28 | 7 | 16611902 | |
| Pubmed | 7.66e-20 | 12 | 28 | 7 | 8245849 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 2471809 | ||
| Pubmed | Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. | 1.66e-19 | 13 | 28 | 7 | 2014240 | |
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 7523540 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 22739040 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 8438572 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 18005734 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 9343822 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 12050368 | ||
| Pubmed | Sequencing and bacterial expression of a novel murine alpha interferon gene. | 1.66e-19 | 13 | 28 | 7 | 18726328 | |
| Pubmed | Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype. | 1.66e-19 | 13 | 28 | 7 | 12930842 | |
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 19706714 | ||
| Pubmed | Organization, structure and expression of murine interferon alpha genes. | 1.66e-19 | 13 | 28 | 7 | 2987810 | |
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 9181467 | ||
| Pubmed | Evidence for a different susceptibility of primate lentiviruses to type I interferons. | 1.66e-19 | 13 | 28 | 7 | 23255800 | |
| Pubmed | Isolation and bacterial expression of a murine alpha leukocyte interferon gene. | 1.66e-19 | 13 | 28 | 7 | 6094686 | |
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 19130550 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 1655578 | ||
| Pubmed | 1.66e-19 | 13 | 28 | 7 | 18572754 | ||
| Pubmed | Interferon induction by HIV glycoprotein 120: role of the V3 loop. | 3.32e-19 | 14 | 28 | 7 | 7526537 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 18200012 | ||
| Pubmed | Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. | 3.32e-19 | 14 | 28 | 7 | 18200009 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 2552026 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 14983024 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 19559726 | ||
| Pubmed | A structural basis for interferon-alpha-receptor interactions. | 3.32e-19 | 14 | 28 | 7 | 17517919 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 25972534 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 15240719 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 7583919 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 16418394 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 18272764 | ||
| Pubmed | Characterization of the murine alpha interferon gene family. | 3.32e-19 | 14 | 28 | 7 | 15254193 | |
| Pubmed | Modulation of interferon-mediated inhibition of human immunodeficiency virus type 1 by Tat. | 3.32e-19 | 14 | 28 | 7 | 7532202 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 2987811 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 11884139 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 16278001 | ||
| Pubmed | Alpha interferon suppresses the cyclin D3 and cdc25A genes, leading to a reversible G0-like arrest. | 3.32e-19 | 14 | 28 | 7 | 8668211 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 19004943 | ||
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 21172865 | ||
| Pubmed | Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer. | 3.32e-19 | 14 | 28 | 7 | 1381203 | |
| Pubmed | 3.32e-19 | 14 | 28 | 7 | 8345204 | ||
| Pubmed | Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis? | 6.22e-19 | 15 | 28 | 7 | 17180012 | |
| Pubmed | 6.22e-19 | 15 | 28 | 7 | 15684736 | ||
| Pubmed | Interferon induction by HIV-1-infected cells: a possible role of sulfatides or related glycolipids. | 6.22e-19 | 15 | 28 | 7 | 8661419 | |
| Pubmed | Role of the Akt pathway in mRNA translation of interferon-stimulated genes. | 6.22e-19 | 15 | 28 | 7 | 18339807 | |
| Pubmed | 6.22e-19 | 15 | 28 | 7 | 9520456 | ||
| Pubmed | 6.22e-19 | 15 | 28 | 7 | 8786318 | ||
| Pubmed | Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. | 1.10e-18 | 16 | 28 | 7 | 18414664 | |
| Pubmed | Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. | 1.10e-18 | 16 | 28 | 7 | 22315404 | |
| Pubmed | Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120. | 1.10e-18 | 16 | 28 | 7 | 7904170 | |
| Pubmed | 1.88e-18 | 17 | 28 | 7 | 22814248 | ||
| Pubmed | Characterization of the type I interferon locus and identification of novel genes. | 1.88e-18 | 17 | 28 | 7 | 15233997 | |
| Pubmed | 3.07e-18 | 18 | 28 | 7 | 1905933 | ||
| Pubmed | 4.86e-18 | 19 | 28 | 7 | 7511078 | ||
| Pubmed | 4.86e-18 | 19 | 28 | 7 | 7815507 | ||
| Pubmed | 4.86e-18 | 19 | 28 | 7 | 1385305 | ||
| Pubmed | 4.86e-18 | 19 | 28 | 7 | 17360657 | ||
| Pubmed | Translational regulation by HIV leader RNA, TAT, and interferon-inducible enzymes. | 4.86e-18 | 19 | 28 | 7 | 1708818 | |
| Pubmed | TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. | 7.47e-18 | 20 | 28 | 7 | 11694501 | |
| Pubmed | 7.47e-18 | 20 | 28 | 7 | 8764000 | ||
| Pubmed | 1.12e-17 | 21 | 28 | 7 | 9108403 | ||
| Pubmed | 1.64e-17 | 22 | 28 | 7 | 7913356 | ||
| Pubmed | 1.64e-17 | 22 | 28 | 7 | 23100517 | ||
| Pubmed | 1.64e-17 | 22 | 28 | 7 | 16160188 | ||
| Pubmed | 2.36e-17 | 23 | 28 | 7 | 9225992 | ||
| Pubmed | PICH Supports Embryonic Hematopoiesis by Suppressing a cGAS-STING-Mediated Interferon Response. | 3.33e-17 | 24 | 28 | 7 | 35037428 | |
| Pubmed | 4.62e-17 | 25 | 28 | 7 | 27183626 | ||
| Pubmed | Modulation of HIV-1 transcription by cytokines and chemokines. | 4.62e-17 | 25 | 28 | 7 | 16375755 | |
| Pubmed | Role of HIV-1 Vpu protein for virus spread and pathogenesis. | 4.62e-17 | 25 | 28 | 7 | 18672082 | |
| Pubmed | The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. | 6.32e-17 | 26 | 28 | 7 | 38744293 | |
| Pubmed | 6.32e-17 | 26 | 28 | 7 | 9658081 | ||
| Pubmed | High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. | 7.07e-17 | 11 | 28 | 6 | 6444699 | |
| Pubmed | 7.07e-17 | 11 | 28 | 6 | 25310498 | ||
| Pubmed | Effect of interferon-alpha on immediate early gene expression of murine cytomegalovirus. | 7.07e-17 | 11 | 28 | 6 | 8389790 | |
| Pubmed | Type I interferon dependence of plasmacytoid dendritic cell activation and migration. | 7.07e-17 | 11 | 28 | 6 | 15795237 | |
| Pubmed | 7.07e-17 | 11 | 28 | 6 | 9794439 | ||
| Pubmed | 7.07e-17 | 11 | 28 | 6 | 18835032 | ||
| Pubmed | The mouse IFN-alpha (Ifa) locus: correlation of physical and linkage maps by in situ hybridization. | 7.07e-17 | 11 | 28 | 6 | 3456887 | |
| Pubmed | Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. | 7.07e-17 | 11 | 28 | 6 | 10448195 | |
| Pubmed | IFN-alpha can both protect against and promote the development of type 1 diabetes. | 7.07e-17 | 11 | 28 | 6 | 19120292 | |
| Pubmed | Mechanism of SUMOylation-Mediated Regulation of Type I IFN Expression. | 7.07e-17 | 11 | 28 | 6 | 36681180 | |
| Pubmed | Decoding type I and III interferon signalling during viral infection. | 8.52e-17 | 27 | 28 | 7 | 30936491 | |
| Pubmed | Aicardi-Goutières syndrome-like encephalitis in mutant mice with constitutively active MDA5. | 8.52e-17 | 27 | 28 | 7 | 33165593 | |
| Pubmed | Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. | 1.14e-16 | 28 | 28 | 7 | 17277142 | |
| Pubmed | 1.14e-16 | 28 | 28 | 7 | 15481145 | ||
| Pubmed | 1.41e-16 | 12 | 28 | 6 | 22685550 | ||
| Pubmed | 1.41e-16 | 12 | 28 | 6 | 3017340 | ||
| Pubmed | 1.41e-16 | 12 | 28 | 6 | 6689487 | ||
| Interaction | IFNA5 interactions | 5.59e-16 | 22 | 27 | 7 | int:IFNA5 | |
| Interaction | IFNA1 interactions | 1.26e-11 | 16 | 27 | 5 | int:IFNA1 | |
| Interaction | IFNA6 interactions | 1.78e-10 | 8 | 27 | 4 | int:IFNA6 | |
| Interaction | IFNA14 interactions | 4.60e-09 | 16 | 27 | 4 | int:IFNA14 | |
| Interaction | IFNA21 interactions | 7.84e-08 | 31 | 27 | 4 | int:IFNA21 | |
| Interaction | LGALS9C interactions | 1.30e-07 | 35 | 27 | 4 | int:LGALS9C | |
| Interaction | IFNA4 interactions | 2.50e-07 | 41 | 27 | 4 | int:IFNA4 | |
| Interaction | IFNA13 interactions | 3.51e-07 | 11 | 27 | 3 | int:IFNA13 | |
| Interaction | IFNA2 interactions | 4.68e-07 | 12 | 27 | 3 | int:IFNA2 | |
| Interaction | RRAGB interactions | 7.72e-07 | 54 | 27 | 4 | int:RRAGB | |
| Interaction | ABCC4 interactions | 8.95e-07 | 56 | 27 | 4 | int:ABCC4 | |
| Interaction | RRAGC interactions | 2.91e-06 | 75 | 27 | 4 | int:RRAGC | |
| Interaction | IFIT3 interactions | 3.77e-06 | 80 | 27 | 4 | int:IFIT3 | |
| Interaction | CD58 interactions | 4.26e-06 | 24 | 27 | 3 | int:CD58 | |
| Interaction | SLC38A9 interactions | 1.36e-05 | 35 | 27 | 3 | int:SLC38A9 | |
| Interaction | SLC12A6 interactions | 2.15e-05 | 124 | 27 | 4 | int:SLC12A6 | |
| Interaction | ANO6 interactions | 2.36e-05 | 127 | 27 | 4 | int:ANO6 | |
| Interaction | SLC12A4 interactions | 2.51e-05 | 129 | 27 | 4 | int:SLC12A4 | |
| Interaction | SLC12A7 interactions | 2.75e-05 | 132 | 27 | 4 | int:SLC12A7 | |
| Interaction | LGALS9B interactions | 2.93e-05 | 45 | 27 | 3 | int:LGALS9B | |
| Interaction | SLC4A2 interactions | 3.00e-05 | 135 | 27 | 4 | int:SLC4A2 | |
| Interaction | SLC9A6 interactions | 3.34e-05 | 47 | 27 | 3 | int:SLC9A6 | |
| Interaction | IFNA17 interactions | 3.61e-05 | 7 | 27 | 2 | int:IFNA17 | |
| Interaction | CLCN3 interactions | 4.28e-05 | 51 | 27 | 3 | int:CLCN3 | |
| Interaction | SLC26A2 interactions | 4.80e-05 | 53 | 27 | 3 | int:SLC26A2 | |
| Interaction | SLC17A5 interactions | 4.82e-05 | 8 | 27 | 2 | int:SLC17A5 | |
| Interaction | ABCB1 interactions | 5.98e-05 | 57 | 27 | 3 | int:ABCB1 | |
| Interaction | IFIT1 interactions | 8.46e-05 | 64 | 27 | 3 | int:IFIT1 | |
| Interaction | MRC2 interactions | 9.70e-05 | 67 | 27 | 3 | int:MRC2 | |
| Interaction | SLC4A7 interactions | 1.00e-04 | 184 | 27 | 4 | int:SLC4A7 | |
| Interaction | MFAP3 interactions | 1.01e-04 | 68 | 27 | 3 | int:MFAP3 | |
| Interaction | LGALS9 interactions | 1.05e-04 | 588 | 27 | 6 | int:LGALS9 | |
| Interaction | IFI44L interactions | 1.13e-04 | 12 | 27 | 2 | int:IFI44L | |
| Interaction | SLC12A2 interactions | 1.25e-04 | 195 | 27 | 4 | int:SLC12A2 | |
| Interaction | ATP2B4 interactions | 1.28e-04 | 196 | 27 | 4 | int:ATP2B4 | |
| Interaction | ALCAM interactions | 1.47e-04 | 77 | 27 | 3 | int:ALCAM | |
| Interaction | SLC44A2 interactions | 2.05e-04 | 16 | 27 | 2 | int:SLC44A2 | |
| Interaction | CD109 interactions | 2.41e-04 | 91 | 27 | 3 | int:CD109 | |
| Interaction | ADAMTS1 interactions | 2.73e-04 | 95 | 27 | 3 | int:ADAMTS1 | |
| Interaction | UBR3 interactions | 3.09e-04 | 99 | 27 | 3 | int:UBR3 | |
| Interaction | TSPAN3 interactions | 3.27e-04 | 101 | 27 | 3 | int:TSPAN3 | |
| Interaction | PLPP2 interactions | 3.93e-04 | 22 | 27 | 2 | int:PLPP2 | |
| Interaction | SLC7A2 interactions | 4.10e-04 | 109 | 27 | 3 | int:SLC7A2 | |
| Interaction | ISG15 interactions | 4.48e-04 | 494 | 27 | 5 | int:ISG15 | |
| Interaction | CD63 interactions | 4.67e-04 | 114 | 27 | 3 | int:CD63 | |
| Interaction | CLCN5 interactions | 5.09e-04 | 25 | 27 | 2 | int:CLCN5 | |
| Interaction | SLC30A1 interactions | 5.17e-04 | 118 | 27 | 3 | int:SLC30A1 | |
| Interaction | HCCS interactions | 5.17e-04 | 118 | 27 | 3 | int:HCCS | |
| Interaction | ENPP4 interactions | 5.51e-04 | 26 | 27 | 2 | int:ENPP4 | |
| Interaction | SLC15A4 interactions | 6.86e-04 | 29 | 27 | 2 | int:SLC15A4 | |
| Interaction | SLC38A5 interactions | 7.85e-04 | 31 | 27 | 2 | int:SLC38A5 | |
| Interaction | LUM interactions | 8.36e-04 | 32 | 27 | 2 | int:LUM | |
| Interaction | IFNAR2 interactions | 9.44e-04 | 34 | 27 | 2 | int:IFNAR2 | |
| Interaction | ATP13A3 interactions | 9.59e-04 | 146 | 27 | 3 | int:ATP13A3 | |
| Interaction | LGALS3 interactions | 1.03e-03 | 340 | 27 | 4 | int:LGALS3 | |
| Interaction | TRPM4 interactions | 1.31e-03 | 40 | 27 | 2 | int:TRPM4 | |
| Interaction | LAMA4 interactions | 1.31e-03 | 40 | 27 | 2 | int:LAMA4 | |
| Interaction | PTPRA interactions | 1.34e-03 | 164 | 27 | 3 | int:PTPRA | |
| Interaction | SEZ6L2 interactions | 1.44e-03 | 42 | 27 | 2 | int:SEZ6L2 | |
| Interaction | CCDC120 interactions | 1.46e-03 | 169 | 27 | 3 | int:CCDC120 | |
| Cytoband | 9p22 | 6.63e-18 | 25 | 28 | 7 | 9p22 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9p21 | 9.98e-13 | 124 | 28 | 7 | chr9p21 | |
| GeneFamily | Interferons | 4.50e-15 | 32 | 22 | 7 | 598 | |
| GeneFamily | Galectins | 2.22e-09 | 15 | 22 | 4 | 629 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_DN | 2.57e-14 | 85 | 28 | 8 | MM684 | |
| Coexpression | SHIN_B_CELL_LYMPHOMA_CLUSTER_5 | 3.91e-13 | 29 | 28 | 6 | MM586 | |
| Coexpression | ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP | 2.67e-12 | 39 | 28 | 6 | M41095 | |
| Coexpression | GROSS_HYPOXIA_VIA_HIF1A_DN | 7.19e-11 | 131 | 28 | 7 | MM1127 | |
| Coexpression | NABA_MATRISOME_ASSOCIATED | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 1.14e-10 | 738 | 28 | 11 | MM17058 |
| Coexpression | NABA_MATRISOME_ASSOCIATED | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 IFNA14 IFNA17 IFNA21 LGALS9 | 1.37e-10 | 751 | 28 | 11 | M5885 |
| Coexpression | NABA_MATRISOME | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 NCAN IFNA14 IFNA17 IFNA21 LGALS9 | 1.69e-10 | 1008 | 28 | 12 | MM17056 |
| Coexpression | NABA_MATRISOME | LGALS9C LGALS9B IFNA2 IFNA4 IFNA5 IFNA6 LGALS3 NCAN IFNA14 IFNA17 IFNA21 LGALS9 | 2.07e-10 | 1026 | 28 | 12 | M5889 |
| Coexpression | LEE_AGING_NEOCORTEX_DN | 2.38e-10 | 80 | 28 | 6 | MM646 | |
| Coexpression | WORSCHECH_TUMOR_REJECTION_UP | 2.38e-10 | 80 | 28 | 6 | MM1229 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_UP | 3.99e-10 | 87 | 28 | 6 | MM652 | |
| Coexpression | IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP | 1.97e-09 | 210 | 28 | 7 | MM751 | |
| Coexpression | ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP | 4.72e-08 | 34 | 28 | 4 | M41094 | |
| Coexpression | NABA_SECRETED_FACTORS | 5.23e-08 | 338 | 28 | 7 | MM17064 | |
| Coexpression | NABA_SECRETED_FACTORS | 5.78e-08 | 343 | 28 | 7 | M5883 | |
| Coexpression | RAO_BOUND_BY_SALL4_ISOFORM_B | 2.07e-06 | 584 | 28 | 7 | MM1080 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_UP | 3.14e-06 | 27 | 28 | 3 | M40935 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP | 5.30e-06 | 32 | 28 | 3 | M40934 | |
| Coexpression | NABA_ECM_AFFILIATED | 2.32e-05 | 158 | 28 | 4 | MM17063 | |
| Coexpression | NABA_ECM_AFFILIATED | 3.10e-05 | 170 | 28 | 4 | M5880 | |
| Coexpression | GOTZMANN_EPITHELIAL_TO_MESENCHYMAL_TRANSITION_DN | 8.74e-05 | 222 | 28 | 4 | MM1132 | |
| Coexpression | MORI_MATURE_B_LYMPHOCYTE_DN | 9.47e-05 | 83 | 28 | 3 | MM596 | |
| Coexpression | BURTON_ADIPOGENESIS_9 | 1.17e-04 | 89 | 28 | 3 | MM1026 | |
| Coexpression | TABULA_MURIS_SENIS_BRAIN_NON_MYELOID_ASTROCYTE_AGEING | 1.32e-04 | 474 | 28 | 5 | MM3685 | |
| Coexpression | MORI_LARGE_PRE_BII_LYMPHOCYTE_UP | 1.33e-04 | 93 | 28 | 3 | MM1137 | |
| Coexpression | HUMMERICH_SKIN_CANCER_PROGRESSION_UP | 1.65e-04 | 100 | 28 | 3 | MM514 | |
| Coexpression | LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN | 1.86e-04 | 19 | 28 | 2 | M40933 | |
| Coexpression | MORI_EMU_MYC_LYMPHOMA_BY_ONSET_TIME_UP | 2.49e-04 | 115 | 28 | 3 | MM599 | |
| Coexpression | MARKEY_RB1_CHRONIC_LOF_DN | 3.57e-04 | 130 | 28 | 3 | MM975 | |
| Coexpression | TABULA_MURIS_SENIS_SKIN_EPIDERMAL_CELL_AGEING | 4.49e-04 | 618 | 28 | 5 | MM3829 | |
| Coexpression | MIKKELSEN_MEF_LCP_WITH_H3K4ME3 | 4.62e-04 | 142 | 28 | 3 | MM840 | |
| Coexpression | GSE3720_UNSTIM_VS_LPS_STIM_VD1_GAMMADELTA_TCELL_DN | 5.01e-04 | 146 | 28 | 3 | M6341 | |
| Coexpression | CHIARADONNA_NEOPLASTIC_TRANSFORMATION_KRAS_DN | 5.01e-04 | 146 | 28 | 3 | MM973 | |
| Coexpression | CHIARADONNA_NEOPLASTIC_TRANSFORMATION_CDC25_DN | 6.54e-04 | 160 | 28 | 3 | MM974 | |
| Coexpression | MIKKELSEN_MCV6_LCP_WITH_H3K4ME3 | 8.34e-04 | 174 | 28 | 3 | MM836 | |
| Coexpression | UEDA_PERIFERAL_CLOCK | 8.76e-04 | 177 | 28 | 3 | MM1145 | |
| Coexpression | PTEN_DN.V1_UP | 1.01e-03 | 186 | 28 | 3 | M2787 | |
| Coexpression | GAUSSMANN_MLL_AF4_FUSION_TARGETS_F_UP | 1.04e-03 | 188 | 28 | 3 | MM983 | |
| Coexpression | GSE17974_IL4_AND_ANTI_IL12_VS_UNTREATED_12H_ACT_CD4_TCELL_DN | 1.09e-03 | 191 | 28 | 3 | M4222 | |
| Coexpression | GSE46025_WT_VS_FOXO1_KO_KLRG1_LOW_CD8_EFFECTOR_TCELL_DN | 1.14e-03 | 194 | 28 | 3 | M9876 | |
| Coexpression | GSE43863_NAIVE_VS_TH1_EFF_CD4_TCELL_D6_LCMV_UP | 1.14e-03 | 194 | 28 | 3 | M9723 | |
| Coexpression | GSE34156_NOD2_LIGAND_VS_TLR1_TLR2_LIGAND_6H_TREATED_MONOCYTE_DN | 1.19e-03 | 197 | 28 | 3 | M8686 | |
| Coexpression | GSE46606_UNSTIM_VS_CD40L_IL2_IL5_3DAY_STIMULATED_IRF4HIGH_SORTED_BCELL_UP | 1.25e-03 | 200 | 28 | 3 | M9831 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-Tuft-related|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.71e-06 | 180 | 28 | 4 | 8ba9bba0c9fecf184a4332ba4585fb2439f68cd3 | |
| ToppCell | 5'-GW_trimst-2-LargeIntestine-Epithelial-Tuft-related-BEST4+_epithelial|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 4.92e-06 | 182 | 28 | 4 | e98ca9df33a1a81fc83ecf73d5141a14f2bc985c | |
| ToppCell | 5'-Adult-LargeIntestine-Epithelial-Tuft-related-BEST4+_epithelial|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.86e-06 | 198 | 28 | 4 | efdbac7a3a02bff4ca48841772e0c136556c2b9b | |
| ToppCell | 5'-Adult-LargeIntestine-Epithelial-Tuft-related|Adult / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 6.86e-06 | 198 | 28 | 4 | a631be84e29c277216d89ec6265bd43e87c1dc86 | |
| Computational | Cell adhesion. | 2.27e-05 | 36 | 17 | 3 | MODULE_410 | |
| Computational | Genes in the cancer module 96. | 2.47e-05 | 37 | 17 | 3 | MODULE_96 | |
| Drug | gunacin | 3.15e-12 | 14 | 27 | 5 | CID000198547 | |
| Drug | pppA2'-5'A2'-5'A | 4.72e-12 | 15 | 27 | 5 | CID000125229 | |
| Drug | podophyllin | 1.34e-11 | 18 | 27 | 5 | CID011979494 | |
| Drug | Nyco | 1.34e-11 | 18 | 27 | 5 | CID000071618 | |
| Drug | L DO | 3.18e-11 | 21 | 27 | 5 | CID000097725 | |
| Drug | formosanin C | 4.11e-11 | 22 | 27 | 5 | CID000073597 | |
| Drug | Hiltonol | 5.25e-11 | 23 | 27 | 5 | CID000431963 | |
| Drug | Yfrkd | 5.47e-11 | 7 | 27 | 4 | CID000129984 | |
| Drug | cycloferon | 6.63e-11 | 24 | 27 | 5 | CID000038072 | |
| Drug | hycanthone | 8.28e-11 | 25 | 27 | 5 | CID000003634 | |
| Drug | ABMP | 1.02e-10 | 26 | 27 | 5 | CID000080567 | |
| Drug | 1hiv | 1.09e-10 | 8 | 27 | 4 | CID005479205 | |
| Drug | Chebi:36708 | 1.09e-10 | 8 | 27 | 4 | CID011966289 | |
| Drug | inosiplex | 1.26e-10 | 27 | 27 | 5 | CID000037510 | |
| Drug | poly rI:rC | 2.21e-10 | 30 | 27 | 5 | CID011979660 | |
| Drug | CHEMBL466993 | 3.12e-10 | 32 | 27 | 5 | CID005320808 | |
| Drug | pipobroman | 3.28e-10 | 10 | 27 | 4 | CID000004842 | |
| Drug | carprofen | 4.31e-10 | 34 | 27 | 5 | CID000002581 | |
| Drug | tilorone | 5.02e-10 | 35 | 27 | 5 | CID000005475 | |
| Drug | flesinoxan | 5.14e-10 | 11 | 27 | 4 | CID000057347 | |
| Drug | pyran | 6.73e-10 | 37 | 27 | 5 | CID000033703 | |
| Drug | anagrelide | 7.74e-10 | 38 | 27 | 5 | CID000002182 | |
| Drug | isofagomine lactam | 8.87e-10 | 39 | 27 | 5 | CID000448980 | |
| Drug | R 842 | 1.11e-09 | 13 | 27 | 4 | CID000130714 | |
| Drug | 1 ind | 1.31e-09 | 42 | 27 | 5 | CID003037877 | |
| Drug | Sesquimustard | 1.48e-09 | 43 | 27 | 5 | CID000019092 | |
| Drug | Lanicemine | 1.56e-09 | 14 | 27 | 4 | CID003038485 | |
| Drug | AC1L9AL3 | 2.10e-09 | 46 | 27 | 5 | CID000441122 | |
| Drug | entecavir | 2.35e-09 | 47 | 27 | 5 | CID000153941 | |
| Drug | Leucine enkephalin | 2.86e-09 | 109 | 27 | 6 | CID000003903 | |
| Drug | adefovir dipivoxil | 2.92e-09 | 49 | 27 | 5 | CID000060871 | |
| Drug | trifluorothymidine | 3.59e-09 | 51 | 27 | 5 | CID000006256 | |
| Drug | YNK01 | 3.69e-09 | 17 | 27 | 4 | CID000084071 | |
| Drug | famciclovir | 3.96e-09 | 52 | 27 | 5 | CID000003324 | |
| Drug | bropirimine | 3.96e-09 | 52 | 27 | 5 | CID000065457 | |
| Drug | Ampligen | 4.37e-09 | 53 | 27 | 5 | CID000038077 | |
| Drug | p203 | 4.74e-09 | 18 | 27 | 4 | CID000019228 | |
| Drug | m IU | 5.81e-09 | 56 | 27 | 5 | CID006852123 | |
| Drug | Lps2 | 6.95e-09 | 58 | 27 | 5 | CID000454710 | |
| Drug | Ciluprevir [USAN] | 7.50e-09 | 20 | 27 | 4 | CID006450803 | |
| Drug | val-mCyd | 7.50e-09 | 20 | 27 | 4 | CID006918726 | |
| Drug | AC1L1U53 | 8.28e-09 | 60 | 27 | 5 | CID000060907 | |
| Drug | AC1L1HZP | 1.15e-08 | 64 | 27 | 5 | CID000004361 | |
| Drug | adefovir | 1.15e-08 | 64 | 27 | 5 | CID000060172 | |
| Drug | AC1O51IP | 1.35e-08 | 66 | 27 | 5 | CID006450363 | |
| Drug | copolymer 1 | 1.35e-08 | 66 | 27 | 5 | CID003081884 | |
| Drug | AC1L1ZCT | 1.64e-08 | 24 | 27 | 4 | CID000038235 | |
| Drug | cycloleucine | 1.69e-08 | 69 | 27 | 5 | CID000002901 | |
| Drug | LB80380 | 1.95e-08 | 25 | 27 | 4 | CID006480442 | |
| Drug | 9-cis-acitretin | 1.96e-08 | 71 | 27 | 5 | CID000041317 | |
| Drug | N6-methyl-(R)-roscovitine | 1.96e-08 | 71 | 27 | 5 | CID005289296 | |
| Drug | 2',3'-dideoxycytidine diphosphate | 2.41e-08 | 74 | 27 | 5 | CID000128494 | |
| Drug | oligoadenylate | 2.57e-08 | 157 | 27 | 6 | CID000107918 | |
| Drug | VX-497 | 2.70e-08 | 27 | 27 | 4 | CID000153241 | |
| Drug | AC1MMF4B | 2.95e-08 | 77 | 27 | 5 | CID003260010 | |
| Drug | AC1NRD2B | 3.15e-08 | 28 | 27 | 4 | CID005289317 | |
| Drug | Zinetac | 3.58e-08 | 80 | 27 | 5 | CID000005039 | |
| Drug | NM 108 | 3.65e-08 | 29 | 27 | 4 | CID000500901 | |
| Drug | polyinosinic-polycytidylic acid | 3.70e-08 | 291 | 27 | 7 | CID000032744 | |
| Drug | DTIC | 3.82e-08 | 81 | 27 | 5 | CID005281007 | |
| Drug | AC1L9FQV | 4.06e-08 | 82 | 27 | 5 | CID000444118 | |
| Drug | penciclovir | 4.21e-08 | 30 | 27 | 4 | CID000004725 | |
| Drug | DZNep | 4.21e-08 | 30 | 27 | 4 | CID000073087 | |
| Drug | glycrrhizin | 5.17e-08 | 86 | 27 | 5 | CID000003495 | |
| Drug | 2'-deoxy-3'-thiacytidine | 5.48e-08 | 87 | 27 | 5 | CID000003877 | |
| Drug | lobucavir | 8.01e-08 | 35 | 27 | 4 | CID000060786 | |
| Drug | NMMA | 8.09e-08 | 94 | 27 | 5 | CID000170607 | |
| Drug | amantadine | 8.54e-08 | 95 | 27 | 5 | CID000002130 | |
| Drug | MCNU | 9.00e-08 | 36 | 27 | 4 | CID000071741 | |
| Drug | A809128 | 9.00e-08 | 36 | 27 | 4 | CID003392279 | |
| Drug | busulfan | 9.48e-08 | 97 | 27 | 5 | CID000002478 | |
| Drug | FMAU | 1.01e-07 | 37 | 27 | 4 | CID000072327 | |
| Drug | fotemustine | 1.13e-07 | 38 | 27 | 4 | CID000104799 | |
| Drug | imidazoquinoline | 1.16e-07 | 101 | 27 | 5 | CID005351568 | |
| Drug | 5H-purin-2-amine | 1.22e-07 | 102 | 27 | 5 | CID000409844 | |
| Drug | DNTB | 1.70e-07 | 216 | 27 | 6 | CID000015325 | |
| Drug | bromcresol green | 1.78e-07 | 110 | 27 | 5 | CID000006451 | |
| Drug | NSC105014 | 1.78e-07 | 110 | 27 | 5 | CID000001546 | |
| Drug | Murabutida | 1.87e-07 | 43 | 27 | 4 | CID005362018 | |
| Drug | NSC 312887 | 1.87e-07 | 43 | 27 | 4 | CID000003368 | |
| Drug | NSC-218321 | 2.13e-07 | 114 | 27 | 5 | CID000004739 | |
| Drug | resiquimod | 2.22e-07 | 115 | 27 | 5 | CID000159603 | |
| Drug | ridostin | 2.32e-07 | 116 | 27 | 5 | CID011979623 | |
| Drug | U-10149A | 3.11e-07 | 123 | 27 | 5 | CID000003928 | |
| Drug | D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 | 3.20e-07 | 49 | 27 | 4 | CID000365716 | |
| Drug | acyclovir | 3.24e-07 | 124 | 27 | 5 | CID000002022 | |
| Drug | methimazole | 3.51e-07 | 126 | 27 | 5 | CID001349907 | |
| Drug | EDSS | 3.95e-07 | 129 | 27 | 5 | CID000123395 | |
| Drug | leucovorin | 4.10e-07 | 130 | 27 | 5 | CID000000143 | |
| Drug | AC1O52EF | 4.22e-07 | 13 | 27 | 3 | CID006450817 | |
| Drug | imiquimod | 4.42e-07 | 132 | 27 | 5 | CID000057469 | |
| Drug | AC1L40MO | 4.59e-07 | 133 | 27 | 5 | CID000099067 | |
| Drug | neopterine | 4.59e-07 | 133 | 27 | 5 | CID000004455 | |
| Drug | THC, delta 9 | 6.36e-07 | 142 | 27 | 5 | CID000002978 | |
| Drug | rosuvastatin | 6.83e-07 | 59 | 27 | 4 | CID000446157 | |
| Drug | EN-1530 | 7.49e-07 | 278 | 27 | 6 | CID000004425 | |
| Drug | emtricitabine | 7.54e-07 | 147 | 27 | 5 | CID000060877 | |
| Drug | cyclohexylammonium | 7.54e-07 | 147 | 27 | 5 | CID000007965 | |
| Drug | AC1Q5H8E | 8.07e-07 | 149 | 27 | 5 | CID000114813 | |
| Drug | 3-aminobenzamide | 1.01e-06 | 156 | 27 | 5 | CID000001645 | |
| Disease | Nephritis | 2.27e-05 | 9 | 24 | 2 | C0027697 | |
| Disease | melanoma | 1.04e-03 | 248 | 24 | 3 | C0025202 | |
| Disease | Myocardial Infarction | 2.70e-03 | 95 | 24 | 2 | C0027051 | |
| Disease | Pancreatic Neoplasm | 2.99e-03 | 100 | 24 | 2 | C0030297 | |
| Disease | Malignant neoplasm of pancreas | 3.11e-03 | 102 | 24 | 2 | C0346647 | |
| Disease | Bladder Neoplasm | 5.76e-03 | 140 | 24 | 2 | C0005695 | |
| Disease | Malignant neoplasm of urinary bladder | 5.84e-03 | 141 | 24 | 2 | C0005684 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| EADFSIHFNRFNPDG | 1561 | Q5SW79 | |
| DANFGQHPFVFDIED | 326 | Q96S59 | |
| SQHDFRTPEFEEFNG | 41 | Q4KMQ2 | |
| RHDFEFPQEEFDGNQ | 56 | P01570 | |
| PAAQEDNDHARDGFQ | 41 | Q9BQS6 | |
| NDIAFHFNPRFEDGG | 56 | Q6DKI2 | |
| AEFGEEDLFHQQGDP | 596 | Q03252 | |
| RGNDVAFHFNPRFNE | 151 | P17931 | |
| NDIAFHFNPRFEDGG | 56 | Q3B8N2 | |
| NDIAFHFNPRFEDGG | 56 | O00182 | |
| RHDFGFPQEEFDGNQ | 56 | P01568 | |
| RHDFGFPQEEFDGNQ | 56 | P01562 | |
| DRDFQGNHFDQYEEG | 11 | Q9UKJ3 | |
| RHDFGFPQEEFDGNQ | 56 | P01569 | |
| TNVFGPHDNFNIEDG | 171 | Q13630 | |
| EQNFHPEFDGYEPGE | 481 | Q32M88 | |
| THGFDDNGRNFDKNG | 616 | Q495T6 | |
| RHDFGFPQEEFGNQF | 56 | P01563 | |
| HEFFGGNNPFSEFFD | 101 | P59910 | |
| NDIGPFGERDDQQVF | 486 | Q9Y597 | |
| RHDFGLPQEEFDGNQ | 56 | P01571 | |
| RHDFRFPQEEFDGNQ | 56 | P05013 | |
| APRHLQAAFEDGFDN | 191 | O14594 | |
| GQEQDSFGGHFDENQ | 71 | A8MV57 | |
| RHDFGFPEEEFDGHQ | 56 | P05014 | |
| AADFHGNDFGNDRNH | 76 | O60224 | |
| FFLDQHIPEDDFANG | 111 | Q9P2J2 | |
| EGNFPNRFSGRQFHD | 76 | A0A0A0MS03 | |
| EFNGDGAFLHDNHEQ | 131 | Q9BS31 |